Provided by Tiger Trade Technology Pte. Ltd.

Verastem

5.90
0.0000
Volume:379.52K
Turnover:2.25M
Market Cap:444.39M
PE:-1.48
High:6.02
Open:5.90
Low:5.87
Close:5.90
52wk High:11.25
52wk Low:4.01
Shares:75.32M
Float Shares:57.38M
Volume Ratio:0.42
T/O Rate:0.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9773
EPS(LYR):-3.6580
ROE:-2888.71%
ROA:-66.06%
PB:-28.62
PE(LYR):-1.61

Loading ...

Verastem posts Q3 net loss of $98.5 million

Reuters
·
Nov 04, 2025

BRIEF-Verastem Q3 Net Income USD -98.518 Million

Reuters
·
Nov 04, 2025

Verastem Inc - Qtrly Adj Net Loss $0.54 per Share

THOMSON REUTERS
·
Nov 04, 2025

Verastem Q3 Operating Expenses USD 51.957 Million

THOMSON REUTERS
·
Nov 04, 2025

Verastem price target raised to $15 from $14 at Mizuho

TIPRANKS
·
Oct 29, 2025

Verastem Inc : Mizuho Raises Target Price to $15 From $14

THOMSON REUTERS
·
Oct 29, 2025

BRIEF-Verastem Oncology Announces Encouraging Preliminary Data From Ongoing Phase 1/2A Dose Escalation Trial Of Versus-7375, An Oral Kras G12d (On/Off) Inhibitor, In Patients With Kras G12d Mutant Solid Tumors

Reuters
·
Oct 24, 2025

Verastem Reports Promising Phase 1/2a Trial Data

TIPRANKS
·
Oct 24, 2025

Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial

Reuters
·
Oct 24, 2025

Verastem Inc - Interim Safety and Efficacy Update Planned for First Half of 2026

THOMSON REUTERS
·
Oct 24, 2025

Verastem Oncology Announces Encouraging Preliminary Data From Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral Kras G12d (on/off) Inhibitor, in Patients With Kras G12d Mutant Solid Tumors

THOMSON REUTERS
·
Oct 24, 2025

Verastem Inc - First Two Dose Levels Cleared With No Dose-Limiting Toxicities

THOMSON REUTERS
·
Oct 24, 2025

Verastem Says Median Overall Survival Not Reached in Partner's Phase 1/2 Pancreatic Cancer Study; Shares Fall

MT Newswires Live
·
Oct 21, 2025

Verastem data ‘best-in-class’ despite slight decline, says RBC Capital

TIPRANKS
·
Oct 21, 2025

Verastem: GFH375 resulted in 41% ORR in Phase 1/2 study

TIPRANKS
·
Oct 21, 2025

Guggenheim Reaffirms Their Buy Rating on Verastem (VSTM)

TIPRANKS
·
Oct 20, 2025

Verastem Reports 41% Response Rate in Phase 1/2 Trial of KRAS G12D Inhibitor for Advanced Pancreatic Cancer

Reuters
·
Oct 20, 2025

Verastem Reports 41% Response Rate for KRAS G12D Inhibitor in Advanced Pancreatic Cancer Trial

Reuters
·
Oct 19, 2025

Verastem management to meet with Cantor

TIPRANKS
·
Oct 17, 2025

Verastem Coverage Assumed by Cantor Fitzgerald at Overweight

Dow Jones
·
Oct 16, 2025